… that brain inflammation caused by activation of a protein complex called the NLRP3 inflammasome worsens Parkinson’s disease (PD). Although multiple drugs that target this inflammasome are under development or entering clinical trials, many are not able to enter the brain. This project will establish a …

… cells of the brain called microglia may produce inflammatory factors that are toxic to dopamine neurons. Cannabinoid … the extent of neuroprotection provided by a novel drug targeting cannabinoid type 2 receptors in a model of … models as a next step toward the clinic. Additional Support: This project was selected for a Stern Discovery …

… programs, and Maurizio Facheris , MD, MSc, associate director, research programs. Reporting on it for MJFF will be … Nate Herpich , associate director, research marketing and communications. The primary goals of these type of events, … Mark is also presenting to the patient community about how they can be a part of research through clinical trial …

… sporadic, at least six genes have been recently linked to familial PD. It is believed that a molecular … (Lobianco et al. 2002). This model has been shown to recapitulate the main morphological features of PD, … facilitate the discovery of new therapies for PD. Final Outcome While it was not possible to conclusively determine the …

… Could Parkinson's disease be an autoimmune disorder? A recent study from Columbia University … The investigators, led by David Sulzer, PhD, will next test whether blocking the autoimmune response could impact … progression. These findings build on growing evidence supporting a role of the immune system in PD. Studies have …

… Virtual Reality (VR) allows for training in complex environments, while motivating subjects to perform numerous repetitions of the training tasks under … in patients with PD. Anticipated Outcome: We expect to show that VR-based training is a viable option for enhancing …